期刊文献+

玻璃体腔注射Lucentis辅助治疗新生血管性青光眼 被引量:7

Efficacy of adjunctive intravitreous injection with Lucentis for neovascular glaucoma
下载PDF
导出
摘要 目的:观察玻璃体腔注射Lucentis在治疗新生血管性青光眼(NVG)中的作用。方法:回顾性系列病例分析。25例25眼NVG患者接受玻璃体腔Lucentis 注射(ranibizumab 0.5mg/0.05mL),待虹膜新生血管消退后,根据病情采用不同治疗方式。术后观察虹膜及房角新生血管情况、眼压及视力变化,随访3mo。结果:玻璃体腔注射Lucentis 3~7d后,20例20眼虹膜和房角新生血管完全消退,5例5眼7d后新生血管未完全消退。继续治疗情况如下:复合式小梁切除术14例14眼,玻璃体切割术4例4眼。患者治疗前平均眼压为43.42±10.99mmHg,出院时平均眼压明显下降(14.26±7.64mmHg, P〈0.05),并且在随访3mo时保持稳定(18.76±5.96mmHg,P〈0.05)。随访3mo时,视力较前提高和不变者20眼,视力下降者5眼。手术完全成功21眼,部分成功3眼,失败为1眼。 结论:璃体腔注射Lucentis,可作为治疗NVG的辅助方法,根据不同病情联合其他治疗方法,可有效治疗NVG。 AIM: To observe the clinical efficacy of adjunctive intravitreous injection with Lucentis for the treatment of neovascular glaucoma(NVG). METHODS: The retrospective case series study included 25 eyes of 25 patients who underwentintravitreous injection with Lucentis. Patients firstly received an intravitreous injection with Lucentis(0.5mg/0.05mL), after the regression of neovascularization of the iris, patients accepted different surgical treatments according to different etiopathogenesis condition. Iris, chamber angle neovascularization condition, intraocular pressure, and visual acuity were observed postoperatively. The follow-up duration was 3mo.RESULTS: After 3-7d of intravitreous Lucentis injecting, iris and chamber angle neovascularization was totally faded in 20 cases(20 eyes)and was not completely faded in 5 cases(5 eyes). Additional treatments were compound trabeculectomy(14 cases, 14 eyes), vitrectomy(4 cases, 4 eyes). The patients' mean intraocular pressure was 43.42±10.99mmHg before treatment, which decreased rapidly when they came out of the hospital(14.26±7.64mmHg, P〈0.05)and stabilized during the follow-up 3mo(18.76±5.96mmHg, P〈0.05). Follow-up at 3mo, visual acuity improved or remained in 20 cases(20 eyes)and decreased in 5 cases(5 eyes). The complete success, qualified success and failure were 21 eyes, 3 eyes and 1 eye, respectively.CONCLUSION:Intravitreous injection with Lucentis can be used as an assisted treatment of NVG. According to different etiopathogenesis condition, it is an effective treatment to combine with other treatment methods for NVG.
出处 《国际眼科杂志》 CAS 2014年第6期1077-1079,共3页 International Eye Science
关键词 LUCENTIS 新生血管性青光眼 全视网膜光凝术 Lucentis neovascular glaucoma panretinal photocoagulation
  • 相关文献

参考文献10

  • 1于湛,刘国军,邸霞.玻璃体腔注射Bevicazumab联合玻璃体切除视网膜及睫状体光凝治疗新生血管性青光眼[J].中国实用眼科杂志,2011,29(12):1272-1274. 被引量:22
  • 2Tripathi RC,Li J,Tripathi BJ,et al.Increased level of vascular endothelial growth faetor in aqueous humor of patients with neovascular glaucoma.Ophthalmology1998; 105(20):232-237.
  • 3Sone H,Okuda Y,Kawakanti Y,et al.Vascular endothelial growth factor level in Aqueous humor of diabetic patients with rubeotie glaucoma is markedly elevated.Diabetes Care1996; 19(11):1306-1307.
  • 4Kodjikian L.Neovascular glaucoma treatment in 2012: role of anti-VEGF agents. J Fr Ophthalmol 2013; 36(5):461-465.
  • 5SooHoo JR,Seibold LK,Kahook MY.Recent advances in the management of neovascular glaucoma.Semin Ophthalmol 2013; 28(3):165-172.
  • 6Lüke J,Nassar K,Lüke M,et al.Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma--results from a prospective interventional case series.Graefes Arch Clin Exp Ophthalmol 2013; 251(10):2403-2413.
  • 7Elmekawey H,Khafagy A.Intracameral ranibizumab and subsequent mitomycin C augmented trabeculectomy in neovascular glaucoma. J Glaucoma 2013 Apr 29.\〖Epub ahead of print\〗.
  • 8张秀兰.新生血管性青光眼是否难治[J].中华眼科杂志,2012,48(6):488-491. 被引量:42
  • 9Olmos LC, Lee RK. Medical and surgical treatment of neovascular glaucoma.Int Ophthalmol Clin 2011; 51(3):27-36.
  • 10刘国军,庞凤,杜敏晖,于湛,李成芳,李菊,仇宜解.视网膜中央静脉阻塞与糖尿病视网膜病变所致新生血管性青光眼的临床特点分析[J].中华实验眼科杂志,2013,31(10):968-972. 被引量:17

二级参考文献39

  • 1刘国军,杨光涛,仇宜解,姜国湖,王燕鸣.激光光凝对PDR患者玻璃体和血清中VEGF及PEDF的影响[J].眼科研究,2007,25(8):609-611. 被引量:3
  • 2Sivak-Callcott JA,O'Day DM,Tsai JC.Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma[J].Ophthalmology,2001,108(10):1767-1767.
  • 3Kim DM,Lim KH.Aqueous shunts:single-platemolteno vs ACT-SEB[J].Acta Ophthaml olStand,1995,73(2):277.
  • 4任泽钦.青光眼[M].第一版:人民卫生出版社,2004:451-452.
  • 5Adamis AP,Shima DT.The role of vascular endothelial growth factor in ocular health and disease[J].Retina,2005,25 (2):111-118.
  • 6Hamard P,Baudouin C.Consensus on neovascular glaucoma[J].J Fr Ophthabmol,2000,23(3):289-294.
  • 7Iliev ME,Domig D,Wolf-Schnurrbursch U,et al.Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma[J].Am J Ophthalmol,2006,142:1054-1056.
  • 8Ehlers JP,Spim MJ,Lam A,et al.Combination injectreal bevacizum-ab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma[J].Retina,2008,28(5):696-702.
  • 9Gaspar AZ,Flammer J,Hendrickson P.Regression of rubeosis iridis after trabeculectomy combined with mitomycin-C[J].Ophthalmic Surg Lasers,1996,27:709-712.
  • 10Bartz Schmidt.Pars plana vitreetomy,endolaser coagulation of the retina and the ciliary body combined with silicone oil endotamponade in the treatment of uncontrolled neovascular glaucoma[J].Graefes Arch Clin Exp Ophthalmol,1999,237 (12):969-975.

共引文献73

同被引文献76

  • 1Beer PM, Wong SJ, Hammad AM, et al. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients[J]. Retina, 2006,26(8):871-876.
  • 2Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective[J]. Clin Cancer Res, 2006,12(17):5018-5022.
  • 3Hollanders K, Van Bergen T, Van de Velde S, et al. Bevacizumab revisited: its use in different mouse models of ocular pathologies[J]. Curr Eye Res, 2014,12:1-11.
  • 4Kodjikian L. Neovascular glaucoma treatment in 2012: role of anti-VEGF agents[J]. J Fr Ophtalmol, 2013,36(5):461-465.
  • 5Hayreh SS. Neovascular glaucoma[J]. Prog Retin Eye Res, 2007,26(5):470-485.
  • 6Pai SA, Shetty R, Vijayan PB, et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion[J]. Am J Ophthalmol, 2007,143(4):601-606.
  • 7Masoumi Moghaddam S, Amini A, Morris DL, et al. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer[J]. Cancer Metastasis Rev, 2012,31(1-2):143-162.
  • 8Zhao Y, Zhu CD, Yan B, et al. miRNA -directed regulation of vegf in tilapia under hypoxia condition[J]. Biochem Biophys Res Commun, 2014,454(1):183-188.
  • 9Penn JS, Madan A, Caldwell RB, et al. Vascular endothelial growth factor in eye disease[J]. Prog Retin Eye Res, 2008,27 (4) :331-371.
  • 10Sasamoto Y, Oshima Y, Miki A, et al. Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: A retrospective two-dose comparative study[J]. J Ocul Pharmacol Ther, 2012,28(1):41-48.

引证文献7

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部